IFNG and neoplasm: To identify mechanisms of IFNγ-driven adaptive resistance to α-PD-1, we exposed human (A375 and 501-mel) and mouse (B16-F10, MC38, 5555, and YUMM2.1) tumour cell lines to IFNγ (20 IU/mL for human and 50 IU/mL for mouse cell lines) or BSA continuously for 2 weeks, and subsequently performed RNA sequencing (RNA-seq).